Diabetes & Metabolism Journal (original) (raw)

Table 1. Demographic and clinical characteristics of the study subjects

Values are presented as mean±standard deviation.

NAFL, nonalcoholic fatty liver; NASH, nonalcoholic steatohepatitis; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FIB-4, fibrosis-4 index; NFS, nonalcoholic fatty liver disease (NAFLD) fibrosis score; WBC, white blood cell; hs-CRP, high-sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance; AKR1B10, aldo-keto reductase family 1 member B10; CK-18, cytokeratin 18; ELF, enhanced liver fibrosis; MRI, magnetic resonance imaging; PDFF, proton density fat fraction; MRE, magnetic resonance elastography; LSM, liver stiffness measurement; TE, transient elastography; CAP, controlled attenuation parameter; FAST, FibroScan-AST; MAST, MRI-AST.

P<0.05,

P<0.01 vs. healthy control subjects,

P<0.05,

P<0.01 vs. healthy control subjects,

P<0.05,

P<0.01 vs. NAFL.

Table 2. The performance of blood and imaging biomarkers and their cutoff values for the diagnosis of NASH (n=116)a

NASH, nonalcoholic steatohepatitis; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AKR1B10, aldo-keto reductase family 1 member B10; CK-18, cytokeratin 18; FIB-4, fibrosis-4 index; NFS, nonalcoholic fatty liver disease (NAFLD) fibrosis score; ELF, enhanced liver fibrosis; AST, aspartate aminotransferase; ALT, alanine aminotransferase; MRI, magnetic resonance imaging; PDFF, proton density fat fraction; MRE, magnetic resonance elastography; LSM, liver stiffness measurement; FAST, FibroScan-AST; MAST, MRI-AST.

In a total of 116 subjects in the pooled cohort, 44 patients had NAFLD activity score ≥4, and 11 patients had advanced hepatic fibrosis (F≥3).

Table 3. The performance of blood and imaging biomarkers and their cutoff values for the diagnosis of advanced fibrosis (F3–4) (n=116)a

AUROC, area under the receiver operating characteristic curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AKR1B10, aldo-keto reductase family 1 member B10; CK-18, cytokeratin 18; FIB-4, fibrosis-4 index; NFS, nonalcoholic fatty liver disease (NAFLD) fibrosis score; ELF, enhanced liver fibrosis; AST, aspartate aminotransferase; ALT, alanine aminotransferase; MRE, magnetic resonance elastography; LSM, liver stiffness measurement; FAST, FibroScan-AST; MAST, magnetic resonance imaging-AST.

In a total of 116 subjects in the pooled cohort, 44 patients had NAFLD activity score ≥4, and 11 patients had advanced hepatic fibrosis (F≥3).

Table 4. The diagnostic performance of blood and imaging biomarkers and their cutoff values for high-risk NASH (NAS ≥4 & F ≥2) (n=116)a

NASH, nonalcoholic steatohepatitis; NAS, nonalcoholic fatty liver disease (NAFLD) activity score; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AKR1B10, aldo-keto reductase family 1 member B10; CK-18, cytokeratin 18; FIB-4, fibrosis-4 index; NFS, NAFLD fibrosis score; ELF, enhanced liver fibrosis; AST, aspartate aminotransferase; ALT, alanine aminotransferase; MRI, magnetic resonance imaging; PDFF, proton density fat fraction; MRE, magnetic resonance elastography; LSM, liver stiffness measurement; FAST, FibroScan-AST; MAST, MRI-AST.

In the pooled cohort (n=116), 16 patients had NAS ≥4 and F ≥2, and 19 patients had significant hepatic fibrosis (F≥2).